These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34741635)

  • 1. Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut.
    Nimmo JT; Smith H; Wang CY; Teeling JL; Nicoll JAR; Verma A; Dodart JC; Liu Z; Lin F; Carare RO
    Acta Neuropathol; 2022 Jan; 143(1):55-73. PubMed ID: 34741635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.
    Doucet M; El-Turabi A; Zabel F; Hunn BHM; Bengoa-Vergniory N; Cioroch M; Ramm M; Smith AM; Gomes AC; Cabral de Miranda G; Wade-Martins R; Bachmann MF
    PLoS One; 2017; 12(8):e0181844. PubMed ID: 28797124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
    Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
    Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Multiple System Atrophy a Prion-like Disorder?
    Jellinger KA; Wenning GK; Stefanova N
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Mild Gut Inflammation Accelerates Brain Neuropathology and Motor Dysfunction in α-Synuclein Mutant Mice.
    Kishimoto Y; Zhu W; Hosoda W; Sen JM; Mattson MP
    Neuromolecular Med; 2019 Sep; 21(3):239-249. PubMed ID: 31079293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
    Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
    Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.
    Kim C; Spencer B; Rockenstein E; Yamakado H; Mante M; Adame A; Fields JA; Masliah D; Iba M; Lee HJ; Rissman RA; Lee SJ; Masliah E
    Mol Neurodegener; 2018 Aug; 13(1):43. PubMed ID: 30092810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propagation of pathological α-synuclein in marmoset brain.
    Shimozawa A; Ono M; Takahara D; Tarutani A; Imura S; Masuda-Suzukake M; Higuchi M; Yanai K; Hisanaga SI; Hasegawa M
    Acta Neuropathol Commun; 2017 Feb; 5(1):12. PubMed ID: 28148299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
    Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
    Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
    Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
    BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.
    Rockenstein E; Nuber S; Overk CR; Ubhi K; Mante M; Patrick C; Adame A; Trejo-Morales M; Gerez J; Picotti P; Jensen PH; Campioni S; Riek R; Winkler J; Gage FH; Winner B; Masliah E
    Brain; 2014 May; 137(Pt 5):1496-513. PubMed ID: 24662516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.
    Yu HJ; Thijssen E; van Brummelen E; van der Plas JL; Radanovic I; Moerland M; Hsieh E; Groeneveld GJ; Dodart JC
    Mov Disord; 2022 Jul; 37(7):1416-1424. PubMed ID: 35426173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex.
    Boutros SW; Raber J; Unni VK
    J Parkinsons Dis; 2021; 11(3):1091-1115. PubMed ID: 34057097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
    Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
    Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.
    Mandler M; Valera E; Rockenstein E; Mante M; Weninger H; Patrick C; Adame A; Schmidhuber S; Santic R; Schneeberger A; Schmidt W; Mattner F; Masliah E
    Mol Neurodegener; 2015 Mar; 10():10. PubMed ID: 25886309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
    Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
    Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction.
    Gentzel RC; Toolan D; Jinn S; Schachter JB; Ma L; Kahle PJ; Smith SM; Marcus JN
    Neurobiol Aging; 2021 Oct; 106():12-25. PubMed ID: 34225000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.